Cancer Immunotherapy Market Size To Hold USD 277.1 Bn By 2030

The global cancer immunotherapy market size was exhibited at USD 96.93 billion in 2022 and is expected to hold around USD 277.1 billion by 2030 growing at a CAGR of 12.6% from 2022 to 2030.

Immunotherapy is a treatment method for cancer. It helps the immune system fight cancer. The immune system fight infections and other diseases. Our immune system comprises white blood cells, organs, and tissues of the lymph system. Immunotherapy is a biological therapy. It uses the substances in a lab to boost the immune system and help find and destroy cancer cells. It can treat many different types of cancer. It can also be used in combination with chemotherapy or other cancer treatments. Some immunotherapy treatments slow the growth of cancer cells. Some immunotherapy treatments help the immune system destroy cancer cells. There are various types of immunotherapy, such as cancer vaccines, T-cell therapy, oncolytic virus therapy, non-specific immunotherapy, monoclonal antibodies, and immune checkpoint inhibitors. Immunotherapy has become a vital method of treating some types of cancer. It works better for some types of cancer than for others.

Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/1394

Growth Factors

Factors such as increasing healthcare expenditure, rising cases of cancer, and the growing geriatric population significantly contribute to the cancer Immunotherapy Market growth. In line with this, the surge in access to medical insurance and rapid technological advancements in cancer treatment positively influence market growth across the globe. Furthermore, cancer is the leading cause of death for many people across the world. Increasing incidences of cancer catalyze the demand for immunotherapy. Rising awareness about the benefits of cancer Immunotherapy creates a positive outlook for the market. The growing prevalence of oncology and heavy investments in research and development activities propels market growth. The development of novel oncology therapeutics strengthens the market growth. The presence of a large number of market players favors market growth. The emergence of many companies that support immunotherapy research boosts the overall market growth. The escalating cases of malignant tumors significantly contribute to market growth across the globe. Various government and non-government organizations make efforts to raise awareness to create a positive outlook for the market. The launch of novel treatments for cancer positively influences market growth. Heavy investments in the development of novel therapies catalyze market growth. Various Strategic initiatives by the market players fuel the market growth. The launch of new immune therapies for cancer treatment propels market growth.

Cancer Immunotherapy Market Report Scope

Report Highlights:

• Based on products, monoclonal antibodies dominated the market and accounted for the largest revenue share. It is expected to maintain its dominance in the coming years. This is due to fewer side effects of monoclonal antibodies, their targeted effects, and a high prescription rate. The increased sales of monoclonal antibodies significantly contribute to the segment’s growth. The oncolytic viral therapies & cancer vaccines are expected to witness a promising CAGR in the coming years. This is due to the development of novel treatment regimens. The increasing demand for cancer vaccines and heavy investments by government and non-government sectors significantly contribute to the segment’s growth.
• Based on application, lung cancer dominated the market and accounted for the largest revenue share. This is due to rising cases of lung cancer across the globe. Rapid immunotherapy adoption and increasing awareness about lung cancer treatment significantly contribute to the segment’s growth. The growing product approval and product launch boost the overall market growth.
• Based on distribution channels, hospital pharmacies dominated the market and accounted for the largest revenue share. This is due to the increasing demand for cancer Immunotherapy in hospitals. The rising number of people admitted due to oncology disorders significantly contributes to the growth of the segment. However, the online pharmacy segment is expected to witness a promising CAGR in the coming years. This is due to the increasing popularity of telemedicine, rising digitalization, and internet penetration. The presence of various online pharmacy players drives the segment’s growth.
• Based on end-use, hospitals & clinics dominated the market and accounted for the largest revenue share. This is due to the high prevalence of cancer. Factors such as Increasing awareness about cancer treatment, rising diagnosis of malignancies, and escalating hospitals offering cancer Immunotherapy significantly contribute to the segment’s growth. Cancer research centers are expected to witness a promising CAGR in the coming years. This is due to the rising support activities by government and non-government organizations.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/1394

Regional Snapshots

Based on region, North America dominated the market and accounted for the largest revenue share. This is due to the presence of leading players and the emergence of new market players. The market players undertake strategic initiatives. The increasing cancer prevalence and rising research activities for cancer immunotherapy significantly contribute to the market growth across the region. The development of novel drugs for cancer creates a positive outlook for the market. Asia Pacific is expected to witness a promising CAGR in the coming years. This is due to the increasing geriatric population and the high prevalence of cancer. Factors such as improving healthcare infrastructure and inflating disposable income significantly contribute to market growth across the region.

Market Dynamics:

Driver: Increasing cases of cancer

The rising incidence of cancer significantly contributes to the cancer Immunotherapy Market growth. Cancer is the leading cause of death for many people across the globe. The increasing awareness about the benefits of cancer immunotherapy creates a positive outlook for the market. Rapid demand for cancer immunotherapies over conventional cancer treatments positively influences market growth. The growing number of ongoing clinical trials catalyzes market growth. The increasing geriatric population and rising lung cancer cases propel the market growth.

Opportunity: Rising research and development activities

Rising research and development activities by the market players offer lucrative opportunities for market growth. The increasing research activities in cancer Immunotherapy provide numerous opportunities for market expansion. The introduction of advanced variants and improved healthcare infrastructure significantly contribute to market growth across the globe. The development of new cancer therapies creates a positive outlook for the market.

Restraint: High Cost

The high costs of cancer Immunotherapy manufacturing restrict the market growth. The research and manufacturing costs are very high. The cancer Immunotherapy research and development activities involve a vast amount, hampers the market growth. Research activities require heavy investments, which impedes the cancer immunotherapy market growth.

Challenge: The complexity of cancer limits the immune response

The complex nature of cancer limits the immune response, which challenges the cancer Immunotherapy Market growth. Moreover, the long time for product approval hampers market growth.

Related Reports

• Assisted Reproductive Technology Market 2022 To 2030

https://www.precedenceresearch.com/assisted-reproductive-technology-market

• Smart Inhalers Market 2022 To 2030

https://www.precedenceresearch.com/smart-inhalers-market

• Rehabilitation Equipment Market 2022 To 2030

https://www.precedenceresearch.com/rehabilitation-equipment-market

Key Developments:

• In February 2022, Medigene AG and BioNTech SE partnered to develop T-cell receptor-based immunotherapies. These therapies are for oncology disorders treatment.

Major Key Players

• Amgen, Inc.
• Astrazeneca, PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lily And Company
• F. Hoffmann-La Roche, Ltd
• Pfizer, Inc.
• Johnson & Johnson
• Merck KGAA
• Novartis AG

Market Segmentation

By Technology Type

• Monoclonal Antibodies
• Cytokines & Immunomodulators
• Checkpoint Inhibitors
• Others

By Cancer Type

• Lungs Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End User

• Hospitals
• Clinics
• Cancer Research Centers

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

https://www.precedenceresearch.com/table-of-content/1394

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1394

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333